According to the
report analysis, ‘Digital
Landscape: Multiple Sclerosis’ states that some of the major companies which are currently functioning
in this domain for acquiring the highest share across the globe by treating the
patients of this disease with the advanced technologies include Biogen, Sanofi
Genzyme, Teva, Merck KGaA / EMD Serono, Roche / Genentech, Novartis, Bayer, Mylan,
Sandoz, Almirall, Celgene and several others. Moreover, the digital landscape
of multiple sclerosis report analyzes digital activities undertaken by pharma
in support of disease-modifying therapies for multiple sclerosis.
Multiple sclerosis is
a long lasting which potentially disabling disease of the brain and spinal cord
and the optic nerves in the eyes. The specific symptoms can involve blindness
in one eye, double vision and trouble with sensation, muscle weakness and few
more. Moreover, this disabling can disrupts the potential of the parts of
nervous system to interact or communicate. Whereas, there is no known cure for
multiple sclerosis but treatments attempt to develop the functions after an
attack and cure new attacks. Not only has this, the government and the key
players are keep updating the patients of this disease and general public by
inaugurating the several functions and programs. Furthermore, the government is
establishing new healthcare centers with the advanced technologies and the
current scenario represents the significant growth in the near future.
In the developed countries the digital landscape of multiple sclerosis is
playing effective role in treating the patients. Whereas, in the overall US,
digital pharma support strongly for Multiple Sclerosis patients by good quality
branded and unbranded resources detection, particularly from Teva, Biogen and
Sanofi Genzyme. Patients are well supported by social media, with branded and
most successful Facebook pages from Teva, Norvatis and EMD Serono. Less mobile
app activity seen, with top serving from branded treatment tracker, through the
Bayer’s latest app achieving early success. Moreover, there is little provision
for HCPs in the MS space beyond the branded, with Biogen, Genzyme and Teva
serving the best branded resources. The pharma-sponsored unbranded and mobile
app background are thin and advantages may present to improve or sponsor
content with the principal non-pharma organizations.
In EUCAN the patients of MS are well supported by pharma most important
by those who are in Germany. In the UK and Canada the support is weakest but
the best branded support is seen from Teva, Merck KGaA and Sanofi Genzyme with
the most brand activity which are connected to the patients support programs.
Pharma serves strong unbranded support but no multi-country, local-language
campaigns through the majority of sites are supported by social media. The
landscape of pharma-sponsored mobile app is strong predominantly from Novartis
with the mutual advantages involving disease tracking and reminders.
To know more,
click on the link below:
+91-9015378249
